A Phase I, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection to patients with advanced/metastatic solid tumors or lymphomas
Study of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Sponsor: Novartis and Aduro Biotech
Enrolling: Male and Female Patients
IRB Number: AAAR6676
U.S. Govt. ID: NCT02675439
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn more about the study drug, MIW815 (ADU-S100). The study will identify the dose that can safely be given to people with solid tumors or lymphomas. The study will also see how well MIW815 (ADU-S100) works in people treated.
This study is closed
Matthew Ingham, MD
Do You Qualify?
Do you have a confirmed solid tumor or lymphoma? Yes No
Have you had treatment for your disease before? Or, is there not a standard treatment available for your disease? Yes No
Does your cancer continue to grow? Yes No
Are you willing to have additional biopsies while on study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator